Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Experimental Hematology & Oncology|November 28, 2024
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignanciesHaiqiong Zheng, Houli Zhao, Shi Han, et al.
Frontiers in Oncology|July 19, 2021
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 7, 2021
BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System InvolvementYiyun Wang, Cheng Zu, Xinyi Teng, et al.
Frontiers in Oncology|December 6, 2021
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to RemissionYiyun Wang, Linqin Wang, Yifan Zeng, et al.
International Journal of Hematology|September 10, 2025
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemiaWei Han, Shuyang Wang, Mingming Zhang, et al.
Frontiers in Oncology|November 18, 2021
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant RelapseLijuan Ding, Yiyun Wang, Ruimin Hong, et al.
Cytotherapy|December 10, 2022
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapyLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Cancer Immunology Research|July 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy StudyGuoqing Wei, Yanlei Zhang, Houli Zhao, et al.
Cell Transplantation|January 6, 2024
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline MutationsTingting Yang, Rongrong Chen, Mingming Zhang, et al.
HLA|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical StudyHaiqiong Zheng, Houli Zhao, Xinyi Zhu, et al.
Pageof 4